The InnFocus MicroShunt was developed in collaboration with the University of Miami's Miller School of Medicine, Bascom Palmer Eye Institute. It provides a quick minimally invasive procedure for shunting aqueous humor from the anterior chamber to the same 'gold standard' drainage path used in trabeculectomy for approximately 50 years. The device is made from SIBS, an innovative highly biocompatible material that has been implanted in the body for over 15 years. It was designed to shunt aqueous humor without the need to cut scleral tissue, control suture tension, or utilize patch grafts. It has been implanted alone or in combination with cataract surgery in prospective studies outside the US.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 09/30/15 | $32,800,000 | Series C |
Crown Venture Fund Hoya Corporation Santen Pharmaceuticals | undisclosed |
